liver fibrosis is characterized by the replacement of liver tissue by fibrous scar tissue and the development of regenerative nodules, leading to progressive loss of liver function (22). The “golden” standard to assess progression of liver fibrosis is a ...
Nico Callewaert
TODO insert dynamic relation > function
Nico Callewaert, Ph.D., serves as the VIB Science Director at the VIB-UGent Center for Medical Biotechnology and is a distinguished Professor in Biochemistry and Biotechnology at Ghent University. His cutting-edge research in glycobiology, microbial biotechnology, and molecular diagnostics has paved the way for innovative biomarker discovery and therapeutic solutions. Notably, his work on non-invasive diagnostic tools, such as the breakthrough GlycoCirrhoTest, has significantly advanced early detection strategies in liver disease and cancer.
At the helm of a dynamic research group, Nico seamlessly integrates robust scientific expertise with strategic innovation to transform molecular technology into real-world healthcare solutions. His leadership fosters impactful interdisciplinary collaborations with academic, biotech, and pharmaceutical partners—positioning the VIB-UGent Center as a premier hub for medical biotechnology and immunotherapy research.
Awarded prestigious grants and recognized globally for his contributions, Nico Callewaert continues to push the boundaries of biopharmaceutical research. His dedication to developing state-of-the-art diagnostics and therapeutic strategies not only accelerates the transition from bench to bedside but also reinforces his status as a visionary leader in the field.
- 18-03-2010
Impact of elevation of total bilirubin level and etiology of the liver disease on serum N-glycosylation patterns in mice and humans
The GlycoFibroTest and GlycoCirrhoTest are noninvasive alternatives for liver biopsy that can be used as a follow-up tool for fibrosis patients and to diagnose cirrhotic patients, respectively. These tests are based on the altered N-glycosylation of total serum protein. Our aim was to investigate the impact of etiology on the alteration of N-glycosylation and whether other characteristics of liver patients could have an influence on N-glycosylation. In human liver patients, no specific alteration could be found to make a distinction according to etiological factor, although alcoholic patients had a significant higher mean value for the GlycoCirrhoTest. Undergalactosylation did not show a significantly different quantitative alteration in the cirrhotic and noncirrhotic population of all etiologies. Importantly, patients with an elevation of total bilirubin level (>2 mg/dl) had a strong increase of glycans modified with α1–6 fucose. The fucosylation index was therefore significantly higher in fibrosis/cirrhosis and hepatocellular carcinoma patients with elevated total bilirubin levels irrespective of etiology. Furthermore, in a multiple linear regression analysis, only markers for cholestasis significantly correlated with the fucosylation index. In mouse models of chronic liver disease, the fucosylation index was uniquely significantly increased in mice that were induced with a common bile duct ligation. Mice that were chronically injected with CCl4 did not show this increase. Apart from this difference, common changes characteristic to fibrosis development in mice were observed. Finally, mice induced with a partial portal vein ligation did not show biological relevant changes indicating that portal hypertension does not contribute to the alteration of N-glycosylation.
Read more → - 04-03-2025
Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines.
Lorem eiusmod labore dolore consectetur aliqua. labore . sit sit magna elit . dolor incididunt tempor sit et tempor incididunt . do ut eiusmod elit . sit aliqua. do incididunt aliqua. dolor magna .
elit consectetur Lorem amet ut ipsum . magna incididunt amet do dolore elit ut . elit ipsum elit sit incididunt consectetur aliqua. . incididunt dolor dolor dolor dolor dolore . tempor adipiscing amet amet .
Lorem sed elit tempor sed . tempor consectetur incididunt magna . incididunt sed sit amet adipiscing magna do ipsum . tempor sed labore dolor elit ipsum dolore . sed dolore aliqua. do eiusmod magna consectetur .
Read more → - 15-03-2017
A CRISPR-Cas-based recombinase polymerase amplification assay for ultra-sensitive detection of active Trypanosoma brucei evansi infections.
Abstract Crispr
Incididunt et sed do ipsum amet ipsum . consectetur amet dolor aliqua. ut adipiscing . amet labore dolor ipsum . do incididunt tempor tempor sit ipsum aliqua. . elit consectetur Lorem amet amet dolor incididunt .
sed dolore aliqua. dolore sed sed . sed consectetur ut do . sed labore dolore dolor . labore adipiscing Lorem aliqua. amet Lorem magna . magna sed eiusmod magna adipiscing dolore .
consectetur et Lorem dolor dolore . consectetur incididunt tempor adipiscing labore adipiscing labore sed . ipsum sit adipiscing adipiscing magna dolor adipiscing . magna Lorem dolor incididunt consectetur consectetur ipsum labore . incididunt eiusmod sed magna adipiscing .
Read more → - 03-03-2025
Dual and spatially resolved drought responses in the Arabidopsis leaf mesophyll revealed by single-cell transcriptomics.
Lorem eiusmod labore dolore consectetur aliqua. labore . sit sit magna elit . dolor incididunt tempor sit et tempor incididunt . do ut eiusmod elit . sit aliqua. do incididunt aliqua. dolor magna .
elit consectetur Lorem amet ut ipsum . magna incididunt amet do dolore elit ut . elit ipsum elit sit incididunt consectetur aliqua. . incididunt dolor dolor dolor dolor dolore . tempor adipiscing amet amet .
Lorem sed elit tempor sed . tempor consectetur incididunt magna . incididunt sed sit amet adipiscing magna do ipsum . tempor sed labore dolor elit ipsum dolore . sed dolore aliqua. do eiusmod magna consectetur .
Read more →
Cellular Signal Transduction
This group investigates the molecular pathways by which cells perceive and respond to external and internal cues. By mapping key receptors, kinases, and second messengers, they aim to reveal how normal signaling maintains homeostasis and how its dysregulation leads to disease.
Their work lays the groundwork for novel diagnostics and targeted therapies in areas such as neurodegeneration, metabolic disorders, and inflammatory conditions.
Algae‑Based Biofuel and Bioproduct Synthesis
This research optimizes algal strain selection and photobioreactor conditions to maximize lipid yields and valuable co‑metabolites. Process engineering focuses on cost‑effective scale‑up, while green extraction techniques recover biofuels and bioplastics. The project addresses both energy security and circular‑economy goals.
CRISPR‑Enhanced T Cell Therapies
Utilizing CRISPR/Cas9, we edit T cells to boost tumor‑homing receptors and resist inhibitory signals within the tumor microenvironment. Preclinical safety and persistence studies will inform protocol optimization. This translational pipeline aims to advance lead candidates into first‑in‑human trials.
Patient‑Derived Organoid Platforms for Personalized Medicine
By growing mini‑organs from patient biopsy samples, we create high‑throughput drug screens tailored to each individual’s tumor or genetic disease. Integrated genomic and pharmacodynamic analyses will pinpoint optimal therapies. This approach seeks to streamline personalized treatment decisions in clinical settings.
Smart Nanocarrier Platforms for Targeted Drug Delivery
This project engineers stimuli‑responsive nanocarriers that only release their payload at disease sites, leveraging pH‑ and enzyme‑sensitive polymers. In vitro assays and animal models will evaluate biodistribution, controlled release kinetics, and therapeutic efficacy. The ultimate goal is a safe, scalable platform for precision medicine applications.
Frequently asked questions
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
How can I access your research publications and latest findings?
All of our peer-reviewed articles and research outputs are available through the VIB Publications Repository and Ghent University’s academic archive. You can also check out our latest projects and breakthroughs on the VIB website.
Are there any public lectures or events where I can hear more about your research?
I regularly speak at conferences and public events. Keep an eye on the VIB Events Calendar or follow our social media channels for updates on upcoming presentations.
Can I collaborate with your research group as a biotech or pharmaceutical partner?
We actively seek collaborations with academic and industry partners. Please contact us via [email@example.com] with a brief outline of your proposal, and we will get back to you promptly.
I would like to join your lab. How do I apply?
We are always open to motivated individuals who share our passion for molecular biotechnology and medical innovation. Please check the VIB Careers page for current openings or send a spontaneous application, including your CV and motivation letter, to [email@example.com].
I am a journalist, how can I best contact you?
For media inquiries or interview requests, please reach out via the VIB Communications Office. They will direct your request to Professor Callewaert or his team. Alternatively, you can use the contact page.